Plain-English translation of NCT06995677 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called TYRA-300 to treat a specific type of early-stage bladder cancer. The medication is designed to target bladder cancer cells that have a particular genetic change (in a gene called FGFR3). Researchers want to learn whether this treatment can help people with this type of cancer and whether it is safe.
Early-stage bladder cancer can come back and requires close monitoring and repeated treatments. This trial aims to find a new treatment option that might work better for patients whose cancer has this specific genetic change, potentially offering an alternative to current standard treatments.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take TYRA-300 as a tablet by mouth. You will visit the study clinic regularly so doctors can check how well the medication is working, look for any side effects, and monitor your cancer through imaging and biopsies. The study will involve different dose levels being tested, and your participation will help determine the right dose and whether this treatment is safe and effective for your type of bladder cancer.
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
United States